AAN 2021 | What’s next in ischemic stroke research?

Sean Savitz, MD, The University of Texas Health Science Center, Houston, TX, talks on the promise of cell-based therapies for stroke treatment and the developments likely to occur over the coming years. Prof. Savitz highlights the Phase III MASTERS-2 trial (NCT03545607) of the allogeneic bone marrow-derived adherent stem cell product, MultiStem, for stroke treatment and enhanced recovery, which, if positive, could represent a breakthrough in the field. Prof. Savitz also discusses the need for optimization of the therapies themselves, as well as clinical trial design and patient selection. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.